Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. We provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Business segments
Jun 2026 · $69.7MThe company’s own SEC segment disclosure.
- United States$69.0M99%
- Non Us$726.0K1%
Axogen, Inc. (AXGN) reported revenue of $61M in Q1 2026 (quarter ended Mar 31, 2026), up 27% from the same quarter a year earlier. That came with a gross margin of 75% and net loss of $20M. For the full year FY2025, revenue was $225M (+20% year on year) and net income −$16M. Its largest region in Jun 2026 was United States at $69M, 99% of the disclosed total, well ahead of Non Us at 1.0%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.